Send to

Choose Destination
Zhonghua Yi Xue Za Zhi. 2009 Sep 8;89(33):2337-41.

[Expressions of cyclinB1, FHIT and Ki-67 in 336 gastric carcinoma patients and their clinicopathologic significance].

[Article in Chinese]

Author information

Department of Pathology, General Hospital of PLA, Beijing 100853, China.



To investigate the expressions of cyclinB1, FHIT and Ki-67 in gastric carcinoma and their clinical significance.


Immunohistochemistry (PV6000 method) was used to detect the expressions of cyclinB1, FHIT and Ki-67 in paraffin-embedded gastric carcinoma tissues of 336 cases and paracancerous normal mucosa of 60 cases. All cases were successfully followed up.


The positive expression rates of cyclinB1, FHIT and Ki-67 in gastric carcinoma were 66.1% (222/336), 39.9% (134/336) and 58.3% (196/336) respectively. CyclinB1 and Ki-67 were all correlated with tumor size, differentiation degree, infiltrative depth, clinical stage, lymphatic invasion and distant metastasis (P < 0.05). And FHIT showed a correlation with differentiation degree, lymphatic invasion and clinical stage (P < 0.05). The 5-year survival rate of patients with positive cyclinB1 and Ki-67 expressions were both lower than those with negative expressions (P < 0.05), whereas FHIT had the opposite pattern (P = 0.025). The cyclinB1 expression in gastric carcinoma was positively correlated with the Ki-67 expression (r = 0.249, P = 0.0001). The expressions of cyclinB1 and Ki-67 in carcinoma were significantly higher than those in normal mucosa tissues (P < 0.05), but FHIT had the opposite pattern. Ki-67 was an independent prognostic indicator for post-operative survival time.


CyclinB1, FHIT and Ki-67 may play significant roles in the occurrence and evolution of gastric carcinoma. And they can be used as useful indicators for clinical assessment of tumor biological behaviors and prognosis in patients with gastric carcinoma.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Chinese Medical Association Publishing House Ltd.
Loading ...
Support Center